The Conatus Pharmaceuticals Inc. (CNAT) Upgrade by The Zacks Investment Research
The firm presently has a $2.25 target price on the biotechnology company’s stock. Zacks Investment Research’s price objective would indicate a …
The firm presently has a $2.25 target price on the biotechnology company’s stock. Zacks Investment Research’s price objective would indicate a …